Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $3.58M invested in Sonoma Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 7 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
52% more capital invested
Capital invested by funds: $2.35M → $3.58M (+$1.22M)
5% less funds holding
Funds holding: 19 → 18 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sophrosyne Capital
New York
|
+$523K |
| 2 |
NL
NWAM LLC
Mercer Island,
Washington
|
+$265K |
| 3 |
Morgan Stanley
New York
|
+$245K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$245K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$236K |
| 2 |
OC
Oppenheimer & Co
New York
|
-$139K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$40K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$33K |
| 5 |
BA
Bard Associates
Chicago,
Illinois
|
-$27.2K |
SNOA Hedge Fund Activity: Q1 2014 in Review
18 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2014, worth a combined $3.58M — up 52% from $2.35M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SNOA and 6 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Sophrosyne Capital, opening a new position worth an estimated $523K. The largest seller was BlackRock Institutional Trust, exiting entirely with an estimated $236K sold.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2014, down from 19 in Q4 2013.
- Funds reported $3.58M of Sonoma Pharmaceuticals stock for Q1 2014, up 52% quarter-over-quarter.
- 6 funds opened new Sonoma Pharmaceuticals positions in Q1 2014 and 7 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q1 2014 was Sophrosyne Capital, an estimated $523K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2014 was BlackRock Institutional Trust, an estimated $236K sold.
Based on aggregated 13F filings for Q1 2014.